Samuel A. Wickline

Samuel A. Wickline, MD, is the founder of Trasir Therapeutics, Inc., which was acquired in 2021 and formed the basis for the organization's activities in RNA therapeutics. Before joining Altamira Therapeutics, he was the Director of the USF Health Heart Institute, Associate Dean and Chair in Cardiovascular Medicine, Professor of Cardiovascular Sciences, Molecular Physiology and Pharmacology, and Medical Engineering at the University of South Florida (USF). Previously, he was Professor of Medicine, Physics, Biomedical Engineering, and Cell Biology and Physiology at Washington University, St. Louis.